Novo Nordisk said on Monday all eligible cash-paying customers in the United States can buy its weight-loss drug Wegovy at a ...

Novo Nordisk (NVO), the maker of the blockbuster drug Ozempic, is cutting the price of its weight loss drug by more than half ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

Weight loss gummies claim to burn fat, suppress hunger, and boost your metabolism to help with weight loss, but these ...

Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...

He and his team then compared the diagnoses for hair loss in these patients’ medical records and found that those prescribed ...

Shares of Novo Nordisk slipped in Monday morning trading after the company announced results of its latest weight-loss drug trial. Novo's results from its Redefine 2 late-stage trial of ...

They discuss: How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about Ozempic's and Mounjarno's patent cliffs. The scenarios ...

Mary Long: I'm Mary Long, and that's Motley Fool analyst Karl Thiel. Weight loss drugs like Ozempic and Mounjaro have dominated the news cycle for the past couple of years now, but other GLP-1 ...

Shares of Novo Nordisk fell on Monday, after the Danish pharmaceutical giant said its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes drop ...

Shares of Eli Lilly and Co. (LLY), which makes the rival weight-loss drug Zepbound, declined 2%. Novo Nordisk also said the latest trial showed that 89.7% of those taking CagriSema achieved weight ...

Dr Jack Mosley, a GP registrar, who researched GLP-1 drug brands including Ozempic, Wegovy, Mounjaro and Zepbound with his father, has written the book Food Noise: How Weight Loss Medication And ...